Background Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further ...

Relapsing Multiple Sclerosis: Navigating Treatment Conundrums This activity is supported by an educational grant from Novartis Pharmaceuticals, Inc.

Multiple sclerosis (MS) is a major, immune-mediated, demyelinating disease and the major cause of non-traumatic disability in young adults. Susceptibility to disease is controlled by a variety of ...

After Arthur was diagnosed with ALS, or amyotrophic lateral sclerosis, in 2011, Obergefell became Arthur's caregiver as the incurable condition ravaged his health.

What is ALS? Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that attacks nerve cells and pathways in the brain and spinal cord.

DelveInsight’s, “Amyotrophic Lateral Sclerosis (ALS) – Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral ...

In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in ...

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients ...

Amyotrophic Lateral Sclerosis, often known as Lou Gehrig's disease, is a progressive and fatal neurodegenerative disorder that affects nerve cells in the brain and spinal cord.

Amyotrophic Lateral Sclerosis, often known as Lou Gehrig’s disease, is a progressive and fatal neurodegenerative disorder that affects nerve cells in the brain and spinal cord. ALS leads to the ...